Olaparib
LYNPARZA®
About LYNPARZA®
-
Marketed by AstraZeneca
-
Poly ADP ribose polymerase (PARP) inhibitor
-
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, metastatic breast, metastatic pancreatic or primary peritoneal cancer who have had complete or partial response to platinum-based chemotherapy
Review and approval status
December 16, 2014
First U.S. approval date
December 19, 2014
First E.U. approval date
Constraint date forecast:
- Orphan Drug Exclusivity expiry: 2024 (United States)
- SPC expiries: 2029 (European Union)
- Patent expiries: 2024 (Japan)
Drug Timeline & Success Rates